Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Cancer Chemotherapy and Pharmacology|March 14, 2023
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participantsVassilios Aslanis, Robert J Slack, Alison C MacKinnon, et al.Journal of Medicinal Chemistry|December 12, 2024
Development and Characterization of a High-Affinity Selective Galectin-3 Mouse Tool Compound in Mouse Models of CancerKristoffer Peterson, Ulf J Nilsson, Lise Gravelle, et al.Journal of Medicinal Chemistry|September 26, 2022
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic DiseaseFredrik R Zetterberg, Alison MacKinnon, Thomas Brimert, et al.Cancer Chemotherapy and Pharmacology|August 21, 2024
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)Vassilios Aslanis, Khalid Abd-Elaziz, Robert J Slack, et al.Cancer Research|January 25, 2019
An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 BlockadeLynda Vuong, Eleni Kouverianou, Claire M Rooney, et al.The European Respiratory Journal|November 20, 2020
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosisNikhil Hirani, Alison C MacKinnon, Lisa Nicol, et al.American Journal of Respiratory and Critical Care Medicine|August 16, 2022
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)Erin E Gaughan, Tom M Quinn, Andrew Mills, et al.Pageof 1